Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors

Purpose: The aim of the current study was to examine the prognostic relevance of the CDKN2A tumor suppressor pathway in gastrointestinal stromal tumors (GIST). Experimental Design: We determined the mRNA expression of p1INK4A, p14ARF, CDK4, RB1, MDM2, TP53, and E2F1 by quantitative reverse transcription-PCR in 38 cases of GISTs and correlated the findings with clinicopathologic factors, including mutation analysis of KIT and PDGFRA. Results: The k-means cluster analysis yielded three prognostic subgroups of GISTs with distinct mRNA expression patterns of the CDKN2A pathway. GISTs with low mRNA expression of the CDKN2A transcripts p16INK4A and p14ARF but high mRNA expression of CDK4, RB1, MDM2, TP53, and E2F1 were associated with aggressive clinical behavior and unfavorable prognosis, whereas GISTs with a low mRNA expression of CDK4, RB1, MDM2, TP53, and E2F1 were not. GISTs with a moderate to high mRNA expression of all examined genes also seemed to be associated with unfavorable prognosis. Regarding mutation analysis, we found significant differences in the KIT/PDGFRA genotype among the three clusters. Univariate analysis revealed high expression of E2F1 to be associated with mitotic count, proliferation rate, KIT mutation, and aggressive clinical behavior. These findings on mRNA level could be confirmed by immunohistochemistry. Conclusion: Our findings implicate differential regulation schemes of the CDKN2A tumor suppressor pathway converging to up-regulation of E2F1 as the critical link to increased cell proliferation and adverse prognosis of GISTs.

[1]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[2]  E. Brambilla,et al.  Human ARF binds E2F1 and inhibits its transcriptional activity , 2001, Oncogene.

[3]  A. Papavassiliou,et al.  Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas , 2002, The Journal of pathology.

[4]  A. Hartmann,et al.  Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Fletcher,et al.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Weintraub,et al.  Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.

[7]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[8]  J. Bartek,et al.  Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression , 1996, Molecular and cellular biology.

[9]  J. Fletcher,et al.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) , 2004, Oncogene.

[10]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[11]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[12]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[13]  Tina Hernandez-Boussard,et al.  Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles , 2004, Oncogene.

[14]  Anil K. Jain,et al.  Algorithms for Clustering Data , 1988 .

[15]  W. El-Rifai,et al.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. , 2002, Human pathology.

[16]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[17]  D. Ginsberg,et al.  Transcriptional regulation of AKT activation by E2F. , 2004, Molecular cell.

[18]  L. Larocca,et al.  Role of p16/INK4a in gastrointestinal stromal tumor progression. , 2004, American journal of clinical pathology.

[19]  F. Christians,et al.  E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. , 2001, Genes & development.

[20]  E. Kay,et al.  Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors , 2004, Modern Pathology.

[21]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[22]  J. Nevins,et al.  Specificity in the activation and control of transcription factor E2F-dependent apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Wyllie.  E2F1 selects tumour cells for both life and death , 2002, The Journal of pathology.

[24]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[25]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[26]  J. Nevins,et al.  The E2F1–3 transcription factors are essential for cellular proliferation , 2001, Nature.

[27]  S. Steigen,et al.  Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course , 2003, Modern Pathology.

[28]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[29]  D. Franquemont.  Differentiation and risk assessment of gastrointestinal stromal tumors. , 1995, American journal of clinical pathology.

[30]  S. Bustin.  Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.

[31]  J. Nevins,et al.  Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[33]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[34]  N. L. Thangue,et al.  p14ARF regulates E2F activity , 2002, Oncogene.

[35]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[36]  Goberdhan P Dimri,et al.  Regulation of a Senescence Checkpoint Response by the E2F1 Transcription Factor and p14ARF Tumor Suppressor , 2000, Molecular and Cellular Biology.

[37]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[38]  N. Socci,et al.  Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.

[39]  R. Schneider-Stock,et al.  High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Liu,et al.  Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors , 2005, Oncogene.

[41]  Florian Haller,et al.  Equivalence test in quantitative reverse transcription polymerase chain reaction: confirmation of reference genes suitable for normalization. , 2004, Analytical biochemistry.

[42]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[43]  L. Sobin,et al.  A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential , 2004, Laboratory Investigation.

[44]  Yong-kun Wei,et al.  C-kit gene mutation in human gastrointestinal stromal tumors. , 2004, World journal of gastroenterology.

[45]  F. Kaye,et al.  Inhibition of cyclin D-CDK 4 / CDK 6 activity is associated with an E 2 F-mediated induction of cyclin kinase inhibitor activity ( human papillomaviruses / cervical cancer / E 7 oncoprotein / retinoblastoma protein ) , 2022 .

[46]  R. Spang,et al.  Role for E2F in Control of Both DNA Replication and Mitotic Functions as Revealed from DNA Microarray Analysis , 2001, Molecular and Cellular Biology.

[47]  David M. Livingston,et al.  p19ARF targets certain E2F species for degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[49]  Tae Won Kim,et al.  Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors , 2004, Clinical Cancer Research.

[50]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[51]  E. Wardelmann,et al.  Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.